ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO147

Cardiovascular Disease Risk Factors in Pediatric Glomerular Disease: An Early Analysis of the Cure Glomerulonephropathy (CureGN) Study

Session Information

Category: Glomerular

  • 1005 Clinical Glomerular Disorders


  • Ashoor, Isa, Children's Hospital of New Orleans, New Orleans, Louisiana, United States
  • Weaver, Donald J., Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States
  • Kogon, Amy, Nationwide Children's Hospital, Columbus, Ohio, United States
  • Parekh, Rulan S., The Hospital For Sick Children, Toronto, Ontario, Canada
  • Vasylyeva, Tetyana L., Texas Tech University Health Sciences Center, Amarillo, Texas, United States
  • Chishti, Aftab S., University of Kentucky , Lexington, Kentucky, United States
  • Rheault, Michelle N., University of Minnesota, Minneapolis, Minnesota, United States
  • Sethna, Christine B., Cohen Children's Medical Center of NY, New Hyde Park, New York, United States
  • O'Shaughnessy, Michelle M., Stanford University Medical Center, Palo Alto, California, United States
  • Helmuth, Margaret, Arbor Research Collaborative for Health, Ann Arbor, Michigan, United States

Group or Team Name

  • CureGN Study Cardiovascular Working Group

Chronic kidney disease (CKD) is major risk factor for subsequent development of cardiovascular disease (CVD). We sought to describe the burden of CVD risk factors in pediatric glomerular disease.


CureGN is a prospective multi-center cohort of biopsy-confirmed primary glomerular diseases (minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and IgA Nephropathy/Vasculitis (IgAN/IgAV)). Descriptive statistics are used to assess CVD risk factors (hypertension, obesity, dyslipidemia, prematurity, and second hand tobacco exposure) and management practices among 578 participants under age 18. Data were obtained at enrollment.


The Table summarizes baseline characteristics and prevalence of CVD risk factors overall and by primary glomerular disease.
Prevalent cardiac disease was rarely reported. Overall, 20% had a history of hypertension. Enrollment BPs were hypertensive in 21% and pre-hypertensive in 14% of patients compared to 1.6% and 9.6% of general pediatric population. Among those with hypertensive readings, and those with UPCR>3.5, less than a third received RAAS blockers overall.
Obesity was present in 31% and elevated total cholesterol (TC > 200 mg/dL) was present in 30% compared to 17% and 7.4% of general pediatric population. Use of lipid lowering medications in children with TC > 200 was infrequent (7%). Prematurity and second hand smoke exposure were similar to general population.


In this pediatric glomerular disease cohort, prevalence of traditional CVD risk factors is high, particularly hypertension and dyslipidemia. Further study is needed to optimize screening and management of CVD risk factors in this population.


  • NIDDK Support